Loading organizations...
§ Venture Capital · New York City, NY, USA
Venture capital firm providing financing and strategic support for clinical-stage biopharmaceutical and life sciences companies.
Aisling Capital is a venture capital firm based in New York, New York, that invests primarily in clinical-stage biopharmaceutical companies and innovative life sciences technologies. The firm provides seed and venture financing, structured debt, royalty deals, and leveraged buyouts to development-stage businesses addressing unmet medical needs across therapeutics, biologics, and medical devices. Operating with a dedicated team of approximately 15 to 20 employees, the organization generates an estimated $5.6 million in annual revenue and manages investments across both private and public healthcare markets. Across its multiple active funds, the firm has raised over $1.8 billion in committed capital and maintains a historical roster of 134 portfolio companies, including recognizable industry names such as Loxo Oncology, BridgeBio Pharma, Prothena, and Aclaris Therapeutics. Aisling Capital was officially established in the year 2000 by founder Dennis Purcell.
Key people at Aisling Capital.
Aisling Capital was founded in 2000 by Dennis Purcell (Founder & Senior Advisor).
Aisling Capital is a New York-based private equity and venture capital firm founded in 2000 that specializes in mid-market and growth-stage investments primarily in the life sciences, healthcare, and biotechnology sectors. The firm’s mission centers on capitalizing on transformative advances in healthcare, particularly those emerging from biotechnology innovations such as those enabled by the Human Genome Project. Aisling Capital invests across the United States and Western Europe, supporting companies developing new therapeutics, pharmaceuticals, diagnostics, and medical technologies. Their investment philosophy emphasizes backing companies that address serious illnesses through innovative approaches, aiming to drive significant improvements in diagnosis, prevention, and treatment. This focus positions Aisling Capital as a key player in fueling the growth and commercialization of cutting-edge healthcare solutions, thereby impacting the startup ecosystem by providing critical capital and expertise to emerging healthcare companies[1][2][4].
Founded in 2000, Aisling Capital was established to leverage the anticipated revolution in healthcare driven by biotechnology breakthroughs. The firm was created by experienced professionals with deep expertise in healthcare and finance, aiming to bridge the gap between scientific innovation and commercial success. Over time, Aisling Capital has evolved to manage multiple funds totaling over $1.8 billion, expanding its geographic reach to include Western Europe alongside the U.S. The firm’s leadership includes managing partners and partners with strong clinical and financial backgrounds, which has helped shape its focus on mid-market and growth-stage companies in healthcare and life sciences[1][2][4].
Aisling Capital rides the wave of rapid innovation in biotechnology and healthcare, a sector undergoing profound transformation due to advances in genomics, personalized medicine, and novel therapeutics. The timing is critical as the healthcare industry faces increasing demand for innovative solutions to complex diseases, aging populations, and rising healthcare costs. Market forces such as regulatory support for biotech innovation, growing venture interest, and technological breakthroughs favor firms like Aisling Capital that can identify and nurture promising healthcare companies. By providing growth capital and expertise, Aisling Capital influences the broader ecosystem by accelerating the development and commercialization of next-generation healthcare products, thereby shaping the future of medicine[1][2][4].
Looking ahead, Aisling Capital is well-positioned to continue capitalizing on the expanding biotech and healthcare innovation landscape. Trends such as gene editing, cell therapies, digital health integration, and precision medicine will likely shape their investment focus. As healthcare challenges grow more complex, the firm’s ability to support companies through growth stages with both capital and operational expertise will enhance its influence. The firm’s ongoing evolution and fundraises suggest a commitment to maintaining leadership in healthcare investing, potentially expanding into new therapeutic areas and geographies. This trajectory ties back to their founding vision of transforming healthcare through innovation, promising continued impact on the life sciences ecosystem[1][2][4].
Aisling Capital was founded in 2000 by Dennis Purcell (Founder & Senior Advisor).
Key people at Aisling Capital.
Aisling Capital has more than 26 tracked investments across 22 companies. The latest tracked deal is $200.0M Series A Extension in Treeline Biosciences in September 2025.